Robak Ewa, Wierzbowska Agnieszka, Chmiela Magdalena, Kulczycka Liliana, Sysa-Jedrejowska Anna, Robak Tadeusz
Department of Dermatology and Venerology, Medical University of Lodz, Krzemieniecka 5, 94-017 Lodz, Poland.
Mediators Inflamm. 2006;2006(1):17898. doi: 10.1155/MI/2006/17898.
We investigated the serum concentration of total metalloproteinase-9 (tMPP-9), active MMP-9 (aMMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in a group of 41 patients with SLE and 20 healthy controls. Serum levels of tMMP-9 and TIMP-1 were assessed by an enzyme-linked immunosorbent assay (ELISA) and aMMP-9 by fluorometric assay. The tMMP-9 level was lower in SLE patients (mean 262 ng/mL) than in healthy volunteers (mean 325 ng/mL) (P = .048). Similarly, aMMP-9 level was lower in SLE patients (mean 121 ng/mL) than in control group (mean 169 ng/mL) (P = .0355) and lower in active SLE (mean 54 ng/mL) than in inactive disease (mean 99 ng/mL) (P = .033). TIMP-1 level was also lower in SLE patients (mean 181 ng/mL) than in control group (mean 233 ng/mL) (P = .004). In SLE patients, a positive correlation was found between tMMP-9 and aMMP-9 (rho = 0.568; P = .001). We also found a positive correlation of tMMP-9 and TIMP-1 with VEGF concentrations (rho = 0.450, P = .005 and rho = 0.387; P = .018, resp). tMMP-9, aMMP-9, and TIMP-1 serum levels are lower in SLE patients than in healthy control group.
我们对41例系统性红斑狼疮（SLE）患者和20名健康对照者的血清总金属蛋白酶-9（tMPP-9）、活性基质金属蛋白酶-9（aMMP-9）以及金属蛋白酶组织抑制剂-1（TIMP-1）浓度进行了研究。采用酶联免疫吸附测定（ELISA）法评估tMMP-9和TIMP-1的血清水平，采用荧光测定法评估aMMP-9。SLE患者的tMMP-9水平（平均262 ng/mL）低于健康志愿者（平均325 ng/mL）（P = 0.048）。同样，SLE患者的aMMP-9水平（平均121 ng/mL）低于对照组（平均169 ng/mL）（P = 0.0355），活动期SLE患者的aMMP-9水平（平均54 ng/mL）低于非活动期患者（平均99 ng/mL）（P = 0.033）。SLE患者的TIMP-1水平（平均181 ng/mL）也低于对照组（平均233 ng/mL）（P = 0.004）。在SLE患者中，tMMP-9与aMMP-9之间存在正相关（rho = 0.568；P = 0.001）。我们还发现tMMP-9和TIMP-1与血管内皮生长因子（VEGF）浓度呈正相关（分别为rho = 0.450，P = 0.005和rho = 0.387；P = 0.018）。SLE患者的tMMP-9、aMMP-9和TIMP-1血清水平低于健康对照组。
Zotero 插件